Anika Therapeutics Inc (ANIK)vsViatris Inc (VTRS)
ANIK
Anika Therapeutics Inc
$14.48
-2.10%
HEALTHCARE · Cap: $191.73M
VTRS
Viatris Inc
$15.88
-0.13%
HEALTHCARE · Cap: $19.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 12426% more annual revenue ($14.56B vs $116.26M). VTRS leads profitability with a -2.0% profit margin vs -9.5%. VTRS appears more attractively valued with a PEG of 0.14. VTRS earns a higher WallStSmart Score of 50/100 (C-).
ANIK
Hold38
out of 100
Grade: F
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.4%
Fair Value
$32.46
Current Price
$14.48
$17.98 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -8.3% — below average capital efficiency
Earnings declined 50.5%
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIK
The strongest argument for ANIK centers on Price/Book, Altman Z-Score, Debt/Equity. Revenue growth of 13.2% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : ANIK
The primary concerns for ANIK are Market Cap, PEG Ratio, Return on Equity.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
ANIK is growing revenue faster at 13.2% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTRS scores higher overall (50/100 vs 38/100). ANIK offers better value entry with a 68.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anika Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?